<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755181</url>
  </required_header>
  <id_info>
    <org_study_id>352.2067</org_study_id>
    <nct_id>NCT02755181</nct_id>
  </id_info>
  <brief_title>fMRI in Impulsivity</brief_title>
  <official_title>Assessment of Longitudinal Functional Magnetic Resonance Imaging (fMRI) as a Brain Measure for Impulsivity in a Borderline Personality Disorder (BPD) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This study aims to use resting-state and task based functional Magnetic Resonance Imaging&#xD;
      (fMRI) as a tool to evaluate trait characteristics of impulsivity in subjects with borderline&#xD;
      personality disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2016</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Affective Faces Task (AFT) fMRI response</measure>
    <time_frame>up to 5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Monetary Incentive Delay (MID) fMRI task response</measure>
    <time_frame>up to 5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for resting-state functional magnetic resonance imaging (fMRI) activity</measure>
    <time_frame>up to 5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Go/ No Go functional magnetic resonance imaging (fMRI) response</measure>
    <time_frame>up to 5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 4 week follow-up visit for Eye Tracking</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Immediate Memory Task (IMT) behavioral test</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Computerized monetary choice procedure behavioral test</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Stop-signal paradigm behavioral test</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Barratt Impulsiveness Scale v.11 (BIS-11)</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Profile of Mood States behavioral test</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Go/ No Go task behavioral test</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Urgency, Premeditation, Perseverance, Sensation Seeking, and Positive Urgency (UPPS-P) Impulsive behavior Scale, subscale for premeditation</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Urgency, Premeditation, Perseverance, Sensation Seeking, and Positive Urgency (UPPS-P) Impulsive behavior Scale, subscale for perseverance</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Urgency, Premeditation, Perseverance, Sensation Seeking, and Positive Urgency (UPPS-P) Impulsive behavior Scale, subscale for sensation seeking</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability in scores measured as change from baseline to follow-up visit at 4 (+/-1) weeks for Urgency, Premeditation, Perseverance, Sensation Seeking, and Positive Urgency (UPPS-P) Impulsive behavior Scale, subscale for urgency</measure>
    <time_frame>up to 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Impulse Control Disorders</condition>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>BPD</arm_group_label>
    <description>Borderline Personality Disorder as diagnosed by DSM-5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal volunteers</arm_group_label>
    <description>normal volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Experimental</intervention_name>
    <description>with functional imaging and behavioural measurements at baseline and 4 weeks</description>
    <arm_group_label>BPD</arm_group_label>
    <arm_group_label>normal volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        BPD and normal volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy Controls: Volunteers (age 18-50 yrs) in generally good Psychiatric and&#xD;
             non-Psychiatric medical health&#xD;
&#xD;
          -  Borderline Personality Disorder subjects: Research volunteers (age 18-50 yrs) who meet&#xD;
             DSM-5 criteria for Borderline Personality Disorder&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        All Participants:&#xD;
&#xD;
          -  Current medications which affect the central nervous system or vascular activity, such&#xD;
             as anti-depressants, anxiolytics, or blood-pressure medications&#xD;
&#xD;
          -  Positive urine drug screen for cocaine, opioids, amphetamine, and benzodiazepines&#xD;
&#xD;
          -  Positive breathalyzer test for alcohol&#xD;
&#xD;
          -  History of clinically significant neurologic disorders or head trauma with loss of&#xD;
             consciousness greater than 30 minutes&#xD;
&#xD;
          -  Clinically significant non-psychiatric medical disorder requiring ongoing treatment.&#xD;
&#xD;
          -  Unwillingness or inability to sign a written informed consent form&#xD;
&#xD;
          -  Pregnancy as assessed by a urine test for ÃŸ-HCG at each visit&#xD;
&#xD;
          -  Medical or physical contraindications for participation based on medical history&#xD;
             interview, labs, and physical exam&#xD;
&#xD;
          -  Metal fragments or other bodily metal (e.g., pacemaker, orthopedic&#xD;
             prosthesis),claustrophobia, or any other condition that would put the subjects at risk&#xD;
             for MRI scanning&#xD;
&#xD;
        In addition, Healthy Controls excluded, if:&#xD;
&#xD;
          -  DSM-5 diagnoses of Personality Disorders (based on SCID-II)&#xD;
&#xD;
          -  DSM-5 diagnoses based on the SCID-I (including the eating disorders module)&#xD;
&#xD;
          -  History of arrest or incarceration&#xD;
&#xD;
        In addition, Borderline Personality Disorder Subjects excluded if:&#xD;
&#xD;
          -  DSM-5 diagnoses&#xD;
&#xD;
          -  DSM-5 Personality Disorder other than Cluster B Personality disorders&#xD;
&#xD;
          -  Current psychoactive medications&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
    <mesh_term>Impulsive Behavior</mesh_term>
    <mesh_term>Disruptive, Impulse Control, and Conduct Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

